Podcasts about mckesson

Read the full stories at CISOSeries.com This week's Department of Know is hosted by Rich Stroffolino, with guests Montez Fitzpatrick, director, information security, global head of cybersecurity, Energizer Holdings, and Jonathan Waldrop, CISO, Acoustic. Missed the live show? Check it out on YouTube. The Department of Know is live every Friday at 4:00 p.m. ET. Join us each week by registering for the open discussion at CISOSeries.com. A huge thanks to our sponsor, KnowBe4 Your employees have always been the target, but the threats they face are evolving. AI empowers cybercriminals to clone a coworker's voice, fake a video call with your CEO, or personalize a phishing email using details scraped from your own website. KnowBe4's AI-native Security Awareness Training (SAT) fights back with 12 autonomous defense agents that allow you to deliver personalized, relevant, and engaging training that adapts as fast as the threats your people face every day. More than 70,000 organizations trust KnowBe4 worldwide. Find out why at KnowBe4.com.  

This week on the 5BytesPodcast, we cover claims that a staggering 284 million records were stolen in a cyberattack on healthcare giant McKesson, while Meta's ambitious plans to reshape its workforce around AI reportedly ran into trouble. We also discuss Meta testing robots inside its data centres, critical ServiceNow vulnerabilities, a new PowerShell-based attack technique, Microsoft's latest Windows headaches, Tim Cook stepping down as Apple CEO, and much more. Reference Links: https://www.rorymon.com/blog/metas-ai-overhaul-stumbles-284-million-patient-records-allegedly-stolen/

We build the tools that run our world on a sliver of understanding, then trust them with everything.In this episode, Matt talks with his dear friend Blake Whitcomb about the unlikely path from a rigid religious upbringing to the frontier of AI and cybersecurity. Blake shares how being cast out led to a reckoning, how he taught himself the way the internet works by writing commands out by hand in a cell, and how that focus became a clearance, a career, and eventually his own company. Along the way they get into masculinity, power, and why going into your own depths is the real work.Blake is the CEO and co-founder of Prophetic AI, a Denver-based cybersecurity company whose platform analyzes network traffic to catch the earliest signs of an attack before data is stolen or encrypted. A largely self-taught engineer who earned a Navy secret clearance and worked on networks for the Department of Defense and McKesson before founding his company, he has spent more than a decade studying how machines communicate.If his story moves you, follow the show and pass it to someone who needs to hear it. New episodes every two weeks.

Erik Semmel from TAB Computer Systems and Computer Talk with TAB joins us for another Tech Tuesday where he talks with Brian about ShinyHunters stealing 1TB of Data from McKesson. Microsoft DataOne Datacenter caught with its Generators running, and how AI ear-buds can listen to your conversations and take action on your behalf.

Shiny Hunters Claims 284M McKesson Records Stolen, PaperCut Patch Bypassed Again, and White House Bans Foreign Power Grid Tech   Host David Shipley covers multiple cybersecurity headlines: Shiny Hunters claims it breached healthcare giant McKesson via voice phishing, compromised Okta SSO, and accessed Salesforce and Snowflake, allegedly exfiltrating about 1TB and 284 million patient records (records, not unique patients) and demanding a $55M+ ransom, though the claims aren't independently verified. PaperCut issued a second emergency patch after bypasses were found for fixes to two actively exploited vulnerabilities that can be chained for unauthenticated remote code execution; organizations on v23 or earlier must upgrade. Berlin confirms an extortion attempt tied to Rhysida, which claims 5.79TB stolen. WordPress discloses five critical plugin/theme flaws enabling full site takeover, including a 10/10 GiveWP RCE. The White House bans foreign-made bulk power grid equipment over backdoor concerns amid rising critical-infrastructure attacks.   00:00 Top Headlines 00:30 McKesson Breach Fallout 03:18 PaperCut Patch Bypassed 06:02 Berlin Rejects Ransom 07:05 Critical WordPress Takeovers 08:43 Power Grid Tech Ban 10:35 AI Security Weekend Episode Promo 11:10 Closing and Sign Off

The Cybercrime Wire, hosted by Scott Schober, provides boardroom and C-suite executives, CIOs, CSOs, CISOs, IT executives and cybersecurity professionals with a breaking news story we're following. If there's a cyberattack, hack, or data breach you should know about, then we're on it. Listen to the podcast daily and hear it every hour on WCYB. The Cybercrime Wire is brought to you Cybercrime Magazine, Page ONE for Cybersecurity at https://cybercrimemagazine.com. • For more breaking news, visit https://cybercrimewire.com

ServiceNow warns of three maximum severity security vulnerabilities PaperCut zero-day exploited in attacks Healthcare giant McKesson discloses breach Get the full show notes here: https://cisoseries.com/cybersecurity-news-servicenow-vulnerabilities-warning-papercut-zero-day-mckesson-healthcare-breach/ Huge thanks to our episode sponsor, KnowBe4 Your employees have always been the target, but the threats they face are evolving. AI empowers cybercriminals to clone a coworker's voice, fake a video call with your CEO, or personalize a phishing email using details scraped from your own website. KnowBe4's AI-native Security Awareness Training (SAT) fights back with 12 autonomous defense agents that allow you to deliver personalized, relevant, and engaging training that adapts as fast as the threats your people face every day. More than 70,000 organizations trust KnowBe4 worldwide. Find out why at KnowBe4.com.

Carhartt, McKesson, Boston Scientific, Hasbro, and a total of 214 organization had a super week...

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show

Independent pharmacies play a vital role in expanding access to immunizations—during respiratory illness season and throughout the year. In this episode, host Britney Woods talks with Dr. Jessica Hung, clinical pharmacist and owner of Semmes Pharmacy, about building a sustainable vaccination program that supports patient care, strengthens pharmacy workflows, and creates year-round business opportunity. Dr. Hung shares practical strategies for preparing before vaccine season, engaging patients in meaningful conversations, using state immunization registries, managing inventory, empowering technicians, and overcoming common barriers to care. Listeners will walk away with actionable ideas to help strengthen immunization services and make a greater impact in their communities.HostBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartGuestsJessica Hung, PharmDSemmes Pharmacy, Semmes, ALResourcesFor Health Mart pharmacies preparing for vaccination season, the Immunization Resource Kit offers convenient access to practical immunization resources and downloadable references available through my.mckesson.com.Understanding the impact of your immunization program goes beyond the number of vaccines administered. For Health Mart Atlas members, Growing Revenue Opportunities or GRO, can help pharmacies identify vaccine administration revenue opportunities and gain insights into overall immunization program performance, helping connect clinical services with business outcomes. Are you a member of VOS yet? Vaccine Optimization Solution is an optional Health Mart Perk that gives eligible Health Mart members access to contracted discounts on select vaccines – there is no cost to access VOS. It's an easy way to enhance purchasing flexibility and help maximize vaccine savings.Patient access is a critical component of immunization services. For eligible Health Mart pharmacies seeking an immunization collaborative practice agreement option, Health Mart PERK$ offers access to an available CPA solution. This option can help pharmacies explore opportunities to support vaccine administration services and expand patient access to care.Tune into Episode: 8 Vaccines in the Fast Lane: Operational Tips from a Pharmacy Owner Health Mart Pharmacies can access Health Mart University (HMU) for: Helpful CE courses and more on Annual Immunization Update, Virtual Immunization Administration Training, Technician Specialist Vaccine Coordinator Course2026 Annual Immunization Update for Pharmacy Professionals (Pharmacists)2026 Annual Immunization Update for Pharmacy Professionals (Pharmacy Technicians)Health Mart pharmacists to claim their CE credit for weekly Gamechanger episodes GameChangers: Overcoming Barriers to Vaccine HesitancyGameChangers: Timely Updates in Pharmacy-Delivered Immunization Services   ReferencesImmunize.OrgImmunization Information Systems (IIS) to learn about connecting to your state's Immunization RegistryThe views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest happenings in these dynamic sectors, where scientific advancements, regulatory decisions, and strategic business initiatives are continuously reshaping the landscape of healthcare. Starting with a significant regulatory update, the FDA has granted Capricor Therapeutics a three-month extension to review Phase 3 data for Deramiocel, a promising treatment targeting upper limb functionality in Duchenne Muscular Dystrophy (DMD). This decision underscores not only the complexity of analyzing data in neuromuscular diseases but also highlights the stringent requirements for treatments that aim to improve quality of life for patients with conditions like DMD. In other regulatory news, Johnson & Johnson has expanded the label for its monoclonal antibody IMAAvy (nipocalimab) to treat warm autoimmune hemolytic anemia. This approval is based on compelling Phase 2/3 clinical data and emphasizes the growing role of monoclonal antibodies in targeting autoimmune disorders. These developments offer promising new therapeutic avenues and signify a shift towards more precise treatment options. Moving to infection control, GSK's Hibsago (bepirovirsen) has received approval in Japan for chronic hepatitis B. This antisense oligonucleotide aims for a functional cure by targeting the hepatitis B surface antigen, representing a significant leap forward in infectious disease management. Similarly, Biocon Biologics' biosimilar pegfilgrastim has been approved in Japan for supportive care in neutropenia, crucial for cancer patients undergoing chemotherapy. These approvals highlight the global acceptance of biosimilars as effective and cost-efficient alternatives. The business landscape is also evolving with noteworthy partnerships and acquisitions. Lundbeck and Eversana are expanding their AI-driven commercialization efforts across the U.S., reflecting how advanced technologies are becoming integral to marketing strategies. Meanwhile, McKesson's $2.25 billion acquisition of Precision Medicine Group underscores the strategic focus on oncology and personalized medicine—an area poised for substantial growth. Innovation continues with AC Immune's positive Phase 1 data for ACI-19764, an oral NLRP3 inhibitor targeting chronic inflammatory disorders. This advancement could potentially revolutionize treatments for inflammation-related conditions affecting cardiovascular and neurological health. In ophthalmology, Bausch + Lomb is pushing forward with its combination eye drop therapy into Phase 3 trials for dry eye disease, demonstrating resilience and commitment despite earlier challenges. Shifting focus to obesity treatment, Eli Lilly's launch of Foundayo in the UK presents formidable competition to Novo Nordisk's Wegovy. This move signifies an intensifying race in obesity management, with potential implications for market dynamics and revenue streams. On the financial front, Hansa Biopharma is gearing up for a potential Nasdaq IPO as it awaits FDA decisions on its kidney transplant drug candidates. Amidst this backdrop, Massachusetts has seen a 25% surge in biotech venture funding this year despite challenges faced by startups. Turning to scientific breakthroughs, Jazz Pharmaceuticals has secured FDA approval for its HER2 bispecific antibody Ziihera as a first-line treatment for HER2-positive stomach cancer. This represents not only a new treatment paradigm but also positions Jazz Pharmaceuticals favorably within an estimated $2 billion market potential. In judicial updates, Merck and AstraZeneca's legal challenges against Medicare's drug price negotiation authority have been dismissed. This outcome supports efforts to reduce healthcare costs through negotiated pricing—a move that could reshape pharmaceutical pricing strategies significantly. Meanwhile, Sentivera's licensing deal focused on inflammatory diseases illustrates the financial potential and therapeutic promise of targeting inflammation—a pathway implicated in numerous serious health conditions. Geopolitical dynamics also play a role as concerns arise about China potentially outpacing U.S. companies in biotech innovation. Such developments may influence future policy decisions regarding international collaborations and domestic investments. Finally, scientific exploration continues to push boundaries with advancements such as human brain organoids providing new insights into neurological disorders and potential therapies. Eli Lilly's collaboration on trans-amplifying RNA vaccines further highlights RNA technology's expanding role post-mRNA vaccine success during COVID-19. As these stories unfold, they paint a picture of an industry marked by relentless innovation and strategic foresight aimed at improving patient outcomes globally. From regulatory hurdles to cutting-edge science, each development contributes to a healthcare environment that is increasingly dynamic and poised for future breakthroughs. Stay tuned as we continue to track these important stories impacting the world of pharmaceuticals and biotechnology.Support the show

The transition from being a rockstar in your vertical to leading at the C-suite level is one of the hardest jumps in modern business.  Not because you aren't capable, but because the job changes faster than anyone prepares you for, and the timeline to become effective has collapsed from years to months. You used to have a multi-year runway to listen, learn, and settle in. Now the proving ground has accelerated, and you're expected to think enterprise-wide, set direction, shape culture, and operate with conviction almost immediately. And that's where so many leaders get blindsided. They step into the role with deep expertise, strong track records, and every intention of succeeding. But they quickly discover that the behaviors that powered their rise don't automatically translate to the top job.  The stakes are higher, the scrutiny is sharper, and the margin for a slow learning curve is gone. Boards, investors, and teams are already forming judgments before you've even taken your seat. And without realizing it, new executives find themselves operating on outdated instincts in a completely different environment. Bill Koch is a former CEO who now coaches leaders navigating some of the most high-pressure environments. He helps new CEOs compress the transition, build real executive presence, and operate with clarity and confidence. In this episode, we talk about how to accelerate that transition, how to understand how you're actually being perceived, and how to adapt fast enough to avoid losing ground in your first critical months.   You'll also learn; Why the jump from functional mastery to C-suite leadership is so challenging How the timeline for becoming effective has collapsed, and what that means for new executives. The behaviors that helped you rise and why they can quietly derail you in a senior role. How to understand the difference between vertical thinking and enterprise thinking. Why a 360 assessment is often the first real mirror a new executive has ever seen. How boards and teams perceive you long before you think they do Why private equity environments expose leadership weaknesses faster than any other setting. How to cultivate executive presence that signals quiet confidence, not overcompensation. The importance of building a “personal boardroom” to think clearly under pressure.     Guest Bio Bill Koch is an executive coach with more than 25 years of C-suite and senior leadership experience across public companies, private enterprises, and private equity–backed firms. A former CEO himself, Bill brings a rare blend of operational depth, boardroom insight, and executive maturity to his coaching practice. His work centers on one mission: helping high performers become highly effective enterprise leaders. For more than a decade, Bill has served as a trusted advisor to CEOs and senior executives navigating high-pressure, high-visibility roles. He coaches leaders across Fortune 500 companies, growth-stage organizations, and academic institutions—guiding them through pivotal transitions, accelerated timelines, and complex leadership challenges. His clients turn to him to gain clarity, sharpen judgment, and build the confident executive presence required to lead at the top. Bill's clients include American Express, Apple, Boeing, Goldman Sachs, John Deere, Mars, MGM, McKesson, Toyota, and others. To learn more, visit https://www.kochleadership.com/ or read Bill's latest insights on Forbes.  About Your Host Craig Picken is an Executive Recruiter, writer, speaker, and ICF Trained Executive Coach. He is focused on recruiting senior-level leadership, sales, and operations executives in the aviation and aerospace industry. His clients include premier OEMs, aircraft operators, leasing/financial organizations, and Maintenance/Repair/Overhaul (MRO) providers, and since 2008, he has personally concluded more than 400 executive-level searches in a variety of disciplines. Craig is the ONLY industry executive recruiter who has professionally flown airplanes, sold airplanes, and successfully run a P&L in the aviation industry. His professional career started with a passion for airplanes. After eight years' experience as a decorated Naval Flight Officer – with more than 100 combat missions, 2,000 hours of flight time, and 325 aircraft carrier landings – Craig sought challenges in business aviation, where he spent more than 7 years in sales with both Gulfstream Aircraft and Bombardier Business Aircraft. Craig is also a sought-after industry speaker who has presented at Corporate Jet Investor, International Aviation Women's Association, and SOCAL Aviation Association.    Resources For more aerospace industry news & commentary: https://craigpicken.com/insights/.  To learn more about Craig Picken, visit https://craigpicken.com/.      Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm, so our show reaches more people. Thank you! 

Medical billing is becoming an important opportunity for independent pharmacies looking to expand patient care services beyond dispensing and better capture the value of pharmacist-provided care. In this episode of Independent Insights, host Britney Woods introduces a recorded conversation between Marc Crouch, Vice President of Pharmacy Retail Operations and Health Mart VP Pro, and Alyssa Mack, Clinical Pharmacist at Gibbs Pharmacy in Lebanon, Tennessee. Alyssa shares how Gibbs Pharmacy has grown its pharmacy-led clinical service model, including immunizations, point-of-care testing, test-to-treat services, patient consultations, and technician-supported billing workflows. The discussion explores practical lessons from building medical billing capabilities, navigating payer relationships and credentialing, using collaborative practice agreements when needed, and creating workflows that help make medical billing more manageable in a busy independent pharmacy setting. Listeners will hear how medical billing can support sustainable patient care services, why immunizations may be a practical place to start, and how becoming provider ready can help pharmacies deliver, document, and support expanded clinical services over time.HostBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartGuestsMarc CrouchVice President, Pharmacy Retail Operations,Office of Health MartAlyssa Mack, PharmDClinical Pharmacist,Gibbs Pharmacy, Lebanon, TennesseeResourcesHealth Mart Pharmacies interested in unlocking new opportunities with Pharmacy Profiles can learn more here (https://view-su2.highspot.com/viewer/4b7cffbe5cf3491f73da9b1785b27ded) Tune into Episode 20: Provider Ready Now-Residency & Credentialing for Independent Growth  Health Mart Pharmacies can access Health Mart University (HMU) for:  Helpful CE courses and more on Medical Billing, Point of Care Testing, and Test and Treat Health Mart pharmacists to claim their CE credit for weekly Gamechanger episodesThe views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

This is the Pharmacy Podcast Network's coverage of the 2026 McKesson ideaShare! Missed the big event? We've got you covered. McKesson's ideaShare is one of the largest community pharmacy brainstorm events. Empowering current and future independent pharmacists with deeper connections, new ways to innovate, and strength in numbers for the voice of community pharmacy. Join host Todd Eury, CEO of the Pharmacy Podcast Network, as he walks the exhibit hall in Denver Colorado interviewing vendors, attendees, independent pharmacy owners, and industry friends.   Thank you to AAPA, for sponsoring this coverage! In this episode we hear from: Kate Helf - IPC Nancy Lyons - McKesson Mackenzie Hernandez - NimbleRx Mohan Gulati, CEO - Thinkrr.ai Ryan Spaulding, VP Sales - Lumistry Veronica German - McKesson Alex Berce - Good Value Pharmacy Crystal Lennartz, President - Health Mart & Health Mart Atlas Kerolos Ekladious - TJM Labs Marc Essensa, CEO - IPC

This is the Pharmacy Podcast Network's coverage of the 2026 McKesson ideaShare! Missed the big event? We've got you covered.       McKesson's ideaShare is one of the largest community pharmacy brainstorm events. Empowering current and future independent pharmacists with deeper connections, new ways to innovate, and strength in numbers for the voice of community pharmacy.       Join host Todd Eury, CEO of the Pharmacy Podcast Network, as he walks the exhibit hall in Denver Colorado interviewing vendors, attendees, independent pharmacy owners, and industry friends.       Thank you to Independent Pharmacy Cooperative (IPC), for sponsoring this coverage!       In this episode we hear from: Timothy Lawson Metropolis Drugs & IPC Member John Covello Chris Darling - Darling Apothecary Ollin Sykes - Sykes and Company Diana Baumohl - Go Mango Meds Sam Pizzo - LSPedia Emlah Tubuo - Emlah Consulting

This is the Pharmacy Podcast Network's coverage of the 2026 McKesson ideaShare! Missed the big event? We've got you covered. McKesson's ideaShare is one of the largest community pharmacy brainstorm events. Empowering current and future independent pharmacists with deeper connections, new ways to innovate, and strength in numbers for the voice of community pharmacy. Join host Todd Eury, CEO of the Pharmacy Podcast Network, as he walks the exhibit hall in Denver Colorado interviewing vendors, attendees, independent pharmacy owners, and industry friends.   Thank you to AAPA, for sponsoring this coverage!   In this episode we hear from: Kelli Sneed & Shams Shibley - AAPARx John Covello with IPC and Anne Cassity with NCPA Mike Bollinger - LiveOak Bank Shahida Choudhry & Jake Johnson - Palms Pharmacy Blair Thielemier - PQS by Innovaccer Nick Fournarakis - Fagron

What happens when the leader who's supposed to set the tone for the whole team is running on fumes, firing off reactive emails, and operating from survival mode instead of strategy?

This is the Pharmacy Podcast Network's coverage of the 2026 McKesson ideaShare! Missed the big event? We've got you covered.   McKesson's ideaShare is one of the largest community pharmacy brainstorm events. Empowering current and future independent pharmacists with deeper connections, new ways to innovate, and strength in numbers for the voice of community pharmacy.   Join host Todd Eury, CEO of the Pharmacy Podcast Network, as he walks the exhibit hall in Denver Colorado interviewing vendors, attendees, independent pharmacy owners, and industry friends.   Thank you to the Independent Pharmacy Cooperative (IPC), for sponsoring this coverage!   In this episode we hear from:   Mark Kinney - IPC Eddy Sookswat - McKesson Kevin Boesen - Outcomes Nick Secret - IPC Dave Randolph - Dave's Pharmacy Jimmy Pappadeas & David Plotkin - Scripted Samantha Pomeroy - IPC Sallie Rafie - Birth Control Pharmacist

Social determinants of health impact more patients than we often realize—and many of those barriers show up in the pharmacy every day.In this episode of Independent Insights, host Britney Woods, Sr. Manager of Community Pharmacy at McKesson Health Mart, sits down with Jennifer Powell, Lead Clinical Pharmacy Technician and Community Health Worker at Gibbs Pharmacy, to discuss how she and her team are actively bridging these gaps to better support their patients.From helping patients navigate food access and affordability to improving engagement and follow-up, Jenny shares real examples of how this work is helping to improve care and outcomes—and how it can be intentionally integrated into the pharmacy through a Pharmacy Technician Community Health Worker role.Listen to this insightful conversation to learn how adding a Community Health Worker to your team can help support patient care, engagement, and your pharmacy's impact in the community.HostBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartGuestsJennifer Powell, CPhT, CHW, DCCCLead Clinical Pharmacy TechnicianGibbs PharmacyResourcesHealth Mart Pharmacies can access Health Mart University (HMU) for:Helpful CE courses and more on Community Health WorkersHealth Mart pharmacists to claim their CE credit for weekly Gamechanger episodes  ReferencesNational Association of Community Health WorkersHome - NACHW - National Association of Community Health WorkersNational Academy for State Health PoliciesState Community Health Worker Policies  CHW Networks & Associations by StateNetworks and Training Programs - NACHW - National Association of Community Health WorkersCEimpact Community Health Worker TrainingPharmacy-Based Community Health Worker TrainingThe views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

This week on Better Buildings for Humans, host Joe Menchefski sits down with Brian Bucher of WD Partners for a fascinating conversation about the intersection of architecture, branding, operations, and human experience in retail design. Drawing from decades of experience creating immersive spaces for some of the world's most recognizable brands, Brian shares how thoughtful design can shape customer behavior, improve employee well-being, and strengthen emotional connections between people and places.The discussion explores everything from daylighting and glare control to adaptive retail strategies, operational efficiency, workplace comfort, and the evolving role of physical spaces in an increasingly digital world. Brian also dives into scalable design systems, hospitality-driven retail, sustainable reuse, and why great buildings must serve both the people inside them and the communities around them.It's an insightful look at how truly exceptional spaces don't just support business goals — they create memorable, human-centered experiences that people genuinely want to return to.More About Brian BucherSENIOR DIRECTORBrian is skilled at leading creative programs, using his keen understanding of marketing and business strategies. He not only values a project's outcome, but the integrity of the design process and interactions between the client and design teams. He has a high regard for the balance of innovative design and practical real-world solutions that connect with consumers in a meaningful way. As creative director, Brian spends significant time collaborating with client stakeholders, architects and engineers, and marketers to bring solutions to market. His experience encompasses strategy and innovation, concept development, fixtures and merchandising, materials specifications, process development and execution. In addition, Brian's work for Laguna Beach Drugstore, Safeway, Citrine, and EchoPark have been honored with industry awards from NASFM, ISP/VM+SD Magazine, Chain Store Age, and CoreNet Global. Brian has worked with many retail, restaurant and consumer brands, including Hard Rock Café, Yum! Brands, Dell, Mazda, John Deere, McKesson and SEI Investments. His clients at WD include Standard Market, Safeway, Rubios, Kraft, Giant Eagle, Wawa, Krispy Kreme, Buca di Beppo, Sonic Automotive, Cooper's Hawk, Amazon, Target, Stop & Shop and Chartwells.CONTACT:https://www.wdpartners.com/ https://www.linkedin.com/in/brian-bucher-leed-ap-187b356 https://www.facebook.com/brian.bucher.773 Where To Find Us:https://bbfhpod.advancedglazings.com/www.advancedglazings.comhttps://www.linkedin.com/company/better-buildings-for-humans-podcastwww.linkedin.com/in/advanced-glazings-ltd-848b4625https://twitter.com/bbfhpodhttps://twitter.com/Solera_Daylighthttps://www.instagram.com/bbfhpod/https://www.instagram.com/advancedglazingsltdhttps://www.facebook.com/AdvancedGlazingsltd

Join host Dr. Britney Woods, PharmD, Senior Manager on the McKesson Health Mart team, for a special Know Before You Go episode created to help independent pharmacy owners get real value from McKesson ideaShare 2026 - before they even arrive. Featuring Jaime Montuoro, PharmD, Director of Education and Practice Advancement with McKesson/Health Mart, Alanna Douglas, Senior Marketing Manager on the McKesson/Health Mart team, this conversation goes behind the scenes of how ideaShare is intentionally designed for today's independent pharmacies. Tune in to hear what education themes matter most this year, how to build a schedule that balances inspiration with practical implementation, and the inspiration behind the Health Mart Pharmacy of the Year award. Whether it's your first ideaShare or your tenth, this episode will help you show up with a plan and leave ready to put ideas into action back at your pharmacy. HostBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartGuestsJaime Montuoro, PharmDDirector of Education & Practice Advancement McKesson/Health MartAlanna DouglasSr. Marketing Manager McKessonResourcesTune into Episode 23: Community Roots to Clinical Impact – Inside a Pharmacy of the Year Winner featuring Dave Randolph and Mikayla Smith, last year's Health Mart Pharmacy of the Year winners. In this episode, they discuss how they expanded clinical services, fostered staff development, and implemented sustainable solutions for patient care while serving their rural community. Health Mart Pharmacies can access Health Mart University (HMU) to: Enroll in the Independent Insights Podcast Package to conveniently access new monthly podcast episodes and claim continuing education (CE) credit (pharmacists) for weekly GameChangers clinical episodes. Access hundreds of no-cost continuing education courses to help elevate pharmacy staff knowledge and maintain state licensure requirements  ReferencesGo to mckessonideashare.com to learn more and registered attendees can login to the Attendee Hub to start planning your McKesson ideaShare 2026 now.  The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über die neue KI-Offensive von Alphabet, robuste Zeiten für die Baumärkte und das Milliarden-Projekt von OHB. Außerdem geht es um Nvidia, Qualcomm, Amazon, Broadcom, Micron, Arm, Intel, Home Depot, Hornbach Holding, Ottobock, EQT, Uniper, Rheinmetall, SAP, Nemetschek, Atoss Software, Infineon, SMA Solar, Ströer, Eli Lilly, Novo Nordisk, Mondelēz International, Domino's Pizza, McKesson, Cencora, Cardinal Health, Vanguard FTSE All-World UCITS ETF (WKN: A1JX52), JPMorgan EUR Corporate Bond Research Enhanced Index UCITS ETF (WKN: A2N76D), Vanguard EUR Corporate Bond UCITS ETF (WKN: A143JK), VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF (WKN: A2JAHJ) und Amundi Smart Overnight Return UCITS ETF (WKN: LYX0WM). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Join host Dr. Britney Woods, PharmD, Sr. Manager of Community Pharmacy at McKesson Health Mart, for a compelling conversation about the power of automation in independent pharmacies. This episode features special guests Faisal Adam, Pharmacist at Mark's Pharmacy, and Alisha Nanji, Pharmacy Manager with McKesson Canada, who share their firsthand experiences on how thoughtfully implemented automation can help transform daily operations, ease the workload for pharmacy teams, and elevate patient care. Listen in as they explore practical strategies for unlocking real capacity and efficiency in the pharmacy setting and discover how embracing technology can help make a meaningful difference for both your staff and patients.HostBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartGuestsFaisal Adam, PharmDPharmacistMark's PharmacyAlisha Nanji, HBSc, BSc Phm, RPh, (ON/NB)Pharmacy ManagerMcKesson CanadaResourcesYou can learn more about McKesson Pharmacy Automation Services here: https://www.mckesson.com/automation/ ReferencesHealth Mart Pharmacies can access Health Mart University (HMU) for:Helpful CE courses and more on inventory management and workflowHealth Mart pharmacists to claim their CE credit for weekly Gamechanger episodes  The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

Train With Duane!This week on Geek Off The Street, we're with our friend Chris again to talk about Jujutsu Kaisen Season 3! We get into all things like the depth to the story and characters but we also discuss whether or not the animation holds up from the last season! All that and so much more on this week's exciting episode of the GOTS Official Podcast!Podcast Timecodes[4:30] What are we drinking this week?[11:00] Opening Thoughts[12:30] Positives[1:07:25] Negatives[1:46:55] What Are We Into This Week?Check Out These Books!When The Frog and the Snake Meet: A Killing Love! by J. Leroy Tucker!Wilbur  Mckesson's Retribution!Greg Sorber's Mechhaven! Pax Machina Audio Book!Join Us in the Discussion!Email: thegeeksoffthestreet@gmail.comInstagram: @thegotspodSubscribe on Youtube! Like Our Facebook! Twitter: @thegotspodTrent Personal: @trentctuckerMusic: @erictucker__Stuff We MentionedChikara Ramen!Trent Tucker Vlogs!Invincible!Maul Shadow Lord!People We MentionedTree of Dreams Music@chikara_ramen@badicalradness@lights.camera.rant@thenerdlounge2.0@gregerationx@author_wilbur_m@mcpodcast@z_daughter_of_light@mindmattermystery

AI is moving fast, and for a lot of leaders that creates both pressure and possibility. In this episode of Leader Generation, Tessa Burg talks with Rohit Prabhakar, Global Head of Digital Experiences and Capabilities at Visa, about what it really takes to lead transformation when the rules keep changing. They dig into why strong foundations still matter, why connected data is more important than ever and why leaders need to balance quick wins with bigger reimagining. If you're trying to make sense of AI beyond the hype, this conversation is worth your time. Rohit shares practical ways to think about adoption, experimentation and change management without getting stuck in overplanning or unrealistic ROI expectations. It's a thoughtful listen for anyone leading teams, modernizing operations or figuring out how to move forward while bringing people along with them. Leader Generation is hosted by Tessa Burg and brought to you by Mod Op. About Rohit Prabhakar: Rohit Prabhakar is a Fortune 50 CMO and Chief Digital Officer who has generated $1.7B+ in business value by turning customer obsession into revenue growth. Currently leading global digital experiences at Visa, he has transformed marketing, data, AI, and CX across McKesson, Thomson Reuters, and FIS. Rohit's superpower: making customers love the most powerful growth engine. You can reach him at Rohitprabharkar.com or on LinkedIn. About Tessa Burg: Tessa is the Chief Technology Officer at Mod Op and Host of the Leader Generation podcast. She has led both technology and marketing teams for 15+ years. Tessa initiated and now leads Mod Op's AI/ML Pilot Team, AI Council and Innovation Pipeline. She started her career in IT and development before following her love for data and strategy into digital marketing. Tessa has held roles on both the consulting and client sides of the business for domestic and international brands, including American Greetings, Amazon, Nestlé, Anlene, Moen and many more. Tessa can be reached on LinkedIn or at Tessa.Burg@ModOp.com.  

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über den nächsten Taco-Trade, den Absturz der Tech-Titel und die Gewinne von CTS Eventim. Außerdem geht es um AMD, Intel, Nvidia, Micron, Lam Research, ASML, Meta, Alphabet, APA Corporation, Occidental Petroleum, EOG Resources, Valero Energy, Autodesk, Salesforce, CrowdStrike, Fortinet, Netflix, Olaplex Holdings, Henkel, TUI, Siemens Energy, Deutz, Carnival, Wüstenrot & Württembergisch, Jungheinrich, SAP, Deutsche Post, Siemens, Apollo, Blackstone, KKR, SK Hynix, Commerzbank, Apple, Mondelez International, McKesson, Loews, Morgan Stanley, Wells Fargo, Visa, Mastercard, American Express, JPMorgan Chase, Bank of America, Citigroup, General Dynamics und RTX. Hier kostenlos für den AAA-Newsletter anmelden: https://www.businessinsider.de/informationen/newsletter/alles-auf-aktien/ Wir freuen uns an Feedback über aaa@welt.de. Noch mehr „Alles auf Aktien“ findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und - ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast „Deffner&Zschäpitz“ hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

What does it look like to build a pharmacy that not only survives—but thrives?In this episode of Independent Insights, host Britney Woods talks with Dave Randolph, owner of Dave's Pharmacy, and Mikayla Smith, pharmacy manager, about their journey as an independent pharmacy serving rural communities. Together, these Health Mart Pharmacy of the Year award winners discuss expanding clinical services, supporting staff through growth, and finding sustainable ways to meet patient needs when access to care is limited.Through candid stories and practical lessons, this episode highlights how thoughtful advocacy, innovation, and leadership can help strengthen both patient care and the longterm health of an independent pharmacy. HostBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartGuestsDave Randolph, RPhPharmacy OwnerDave's PharmacyMikayla Smith, CPhTAA Business Pharmacy ManagerDave's PharmacyReferencesTune into these additional Independent Insights episodes for more details on ECAPs and hosting a legislator mentioned during this podcast episode:Episode 19: Your Pharmacy, Your Voice: Why HR3164 (ECAPS) Needs YouEpisode 17: From Aisles to Action: Welcoming Legislators into Your Pharmacy The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

Why Collaboration Is the Key to Employer Brand Activation, with Haley de la Grana of McKesson by Jorgen Sundberg

In this episode of Tank Talks, Matt Cohen sits down with Ali Asaria, Co-Founder of Transformer Lab, to unpack the less visible side of the AI boom, from broken machine learning tools to the rise of autonomous research agents. Ali shares what it really looks like inside modern AI development and why the biggest opportunity isn't just using models, but having the ability to train, control, and improve them.Ali also reflects on his journey building across multiple tech waves, from creating BrickBreaker on BlackBerry to scaling Well.ca and Tulip, and now tackling AI infrastructure with Transformer Lab. He breaks down the realities most founders don't talk about, why great products lose deals, how long enterprise sales actually take, and why success often comes down to trust, timing, and people more than technology.Beyond AI, the conversation takes a broader turn into the future of innovation. Ali challenges the tech industry, especially in Canada, to think bigger, rebuild public trust, and focus on solving real-world problems through ambitious “mega projects.” If you're trying to separate AI hype from reality and understand where the real leverage is being created, this episode gives you a much clearer lens.Building BrickBreaker on 150M Devices (00:02:41)How a side project at BlackBerry turned into a global phenomenon. The early lesson that distribution beats perfection. Ali shares how building something simple but widely adopted gave him an early taste of scale. It also shaped his belief that getting into users' hands fast matters more than polishing endlessly in isolation.The Early Days of E-Commerce in Canada (00:05:36)Packing boxes manually, hacking payment systems, and why investors believed e-commerce would never work in Canada. From manually processing credit cards to building infrastructure from scratch, Ali walks through how scrappy the early days really were. It's a reminder that many “obvious” markets today once looked completely unworkable.Scaling Well.ca and the McKesson Exit (00:08:18)How relationships with partners turned into acquisition opportunities. The messy reality behind “successful exits.” Ali explains how long-term partnerships quietly set the stage for acquisition, even before it was intentional. He also highlights how unpredictable and fragile deals can be, even when they seem done.Enterprise Sales Lessons from Tulip (00:11:19)Why great products don't win deals. Trust, relationships, and the human side of multi-million dollar contracts. Ali breaks down how enterprise sales are less about features and more about credibility and relationships built over time. He also shares how incumbents win not because they're better, but because they're already embedded.The Hard Truth About Startup Life (00:13:52)“90% hell, 10% fun.” What founders don't talk about publicly and how to choose the right investors. Behind the highlight reels, Ali emphasizes how difficult the journey really is and how rarely things go to plan. Choosing the right partners becomes critical when things inevitably get hard.The Moment AI Changed Everything (00:16:22)Why language models shattered the belief that human intelligence couldn't be replicated. Ali describes the exact moment his worldview shifted after seeing what LLMs could do. What once felt impossible suddenly became inevitable, changing how he thought about both technology and opportunity.What Transformer Lab Actually Does (00:20:11)Simplifying AI model training, orchestration, and infrastructure across local machines and massive GPU clusters. Ali explains how fragmented and complex current AI workflows are, especially for researchers. Transformer Lab aims to remove that friction and make building models far more accessible and efficient.Scaling AI From One Machine to Thousands (00:23:14)The technical leap required to move from hobbyist experimentation to full-scale AI labs. Moving from a single machine to distributed systems introduces massive complexity most developers never see. Ali breaks down why solving this unlock is essential for the next generation of AI builders.AI Hype vs Reality (00:25:41)Why Ali believes we may already have AGI, and why valuations still don't make sense. Ali challenges the common narrative by arguing we're closer to AGI than people admit. At the same time, he questions whether the current market can realistically justify the valuations we're seeing.Canada's Startup Ecosystem: Challenges & Advantages (00:32:11)Why geography matters less than mindset, and why building is always hard everywhere. Ali pushes back on the idea that location is the primary constraint for founders. Instead, he argues that resilience and ambition matter far more than where you're building from.Why Tech Has Lost Public Trust (00:34:12)From rebels to power players, and what founders must do to rebuild credibility. Ali reflects on how the tech industry's image has shifted over time and why that matters. Rebuilding trust requires focusing on real impact, not just growth or financial wins.The Case for Mega Projects (00:38:09)Why Canada needs bold, visible innovation bets that actually improve everyday life. Ali argues that large-scale, collaborative initiatives could realign public perception and drive meaningful progress. The key is solving problems people actually feel in their daily lives.The Future of AI and Talent Sovereignty (00:41:28)Why owning talent matters more than owning infrastructure in the AI race. Ali emphasizes that long-term advantage comes from people, not just technology or compute. Countries that develop and retain top talent will ultimately shape the future of AI.About Ali AsariaAli Asaria is a serial entrepreneur and one of Canada's most accomplished technology founders. He created the iconic BrickBreaker game on BlackBerry, founded Well.ca (later acquired by McKesson), and built Tulip into a leading enterprise retail platform backed by top-tier investors.He is now the co-founder of Transformer Lab, an open-source platform designed to simplify and scale AI model development. His work focuses on democratizing access to AI infrastructure, enabling developers and organizations to build advanced models without the complexity traditionally required.Ali is known for his bold thinking on AI, startup ecosystems, and the future of technology, often challenging conventional narratives around innovation and scale.Connect with Ali Asaria on LinkedIn: https://www.linkedin.com/in/aliasaria/Visit the Transformer Lab website: https://lab.cloud/Connect with Matt Cohen on LinkedIn: https://ca.linkedin.com/in/matt-cohen1Visit the Ripple Ventures website: https://www.rippleventures.com/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit tanktalks.substack.com

In episode 244, Coffey talks with Dr. Jason Jones about how leaders must adapt their thinking and behavior to navigate the rapid disruption caused by artificial intelligence.  They discuss why AI represents a step-change disruption compared to past technology waves; growing workforce resistance and fear surrounding AI adoption in organizations; how enterprise AI systems will soon integrate SOPs, training, and operational knowledge; the neuroscience behind fear, uncertainty, and cognitive rigidity during change; why leaders must develop cognitive adaptability and emotional regulation; the concept of neuro-adaptive leadership and upgrading the brain's operating system; attuning to disruption through proactive awareness and disruption scanning; decoding thought patterns and identifying hidden biases that block innovation; aligning leadership identity with values to guide behavior under pressure; using reflection, reframing, and replacement to rewire thinking through neuroplasticity; and how leaders can model adaptive thinking to help teams thrive during uncertainty.  For HR teams who discuss this podcast in their team meetings, we've created a discussion starter PDF to help guide your conversation. Download it here https://goodmorninghr.com/EP244  Good Morning, HR is brought to you by Imperative—Bulletproof Background Checks. For more information about our commitment to quality and excellent customer service, visit us at https://imperativeinfo.com.   If you are an HRCI or SHRM-certified professional, this episode of Good Morning, HR has been pre-approved for half a recertification credit. To obtain the recertification information for this episode, visit https://goodmorninghr.com.   About our Guest:  Dr. Jones equips leaders and teams with science-based strategies to activate peak performance, drive engagement, and thrive in the age of disruption. He is a leading authority on NeuroAdaptive Leadership™ and the neuroscience of performance, helping organizations rewire the way their leaders think, act, and inspire others. Dr. Jones is an Organizational Psychologist, executive coach, and international keynote speaker.   Drawing from cutting-edge neuroscience and more than 150 years of motivation and performance research, Dr. Jones has developed a practical and engaging approach to leadership that helps people understand and optimize how the brain drives behavior, influence, and decision-making. His approach has been used by Fortune 500 companies and forward-thinking organizations around the world, helping empower leaders to bring out the best in themselves and those they lead.  As the founder and CEO of LeaderPath, Dr. Jones has worked with some of the world's most recognized brands, including Microsoft, IBM, Porsche, AT&T, American Airlines, McKesson, Seagate Technology, and the Dallas Cowboys. His work has been featured by Inc. Magazine, FOX, CBS, ABC, and PBS, and his thought leadership continues to shape how modern leaders adapt, connect, and perform in an ever-changing world.  He is the two-time best-selling author of "Activator: Using Brain Science to Boost Motivation, Deepen Engagement, and Supercharge Performance" and "28 Days to a Motivated Team."   Prior to founding LeaderPath, Dr. Jones led executive education at AT&T, where he was responsible for developing more than 6,000 leaders globally, contributing to AT&T being named the #1 Learning Organization in America by Chief Learning Officer Magazine.  Outside of his work, Jason enjoys traveling, outdoor adventures, spending time with his grown children, and fueling his passion for helping others live and lead with purpose, resilience, and flow.  Dr. Jason Jones can be reached at https://drjasonjones.com  https://www.linkedin.com/in/DrJasonJones1  https://www.instagram.com/drjjones  https://www.youtube.com/c/DrJasonJones1   About Mike Coffey:  Mike Coffey is an entrepreneur, licensed private investigator, business strategist, HR consultant, and registered yoga teacher. In 1999, he founded Imperative, a background investigations and due diligence firm helping risk-averse clients make well-informed decisions about the people they involve in their business. Imperative delivers in-depth employment background investigations, know-your-customer and anti-money laundering compliance, and due diligence investigations to more than 300 risk-averse corporate clients across the US, and, through its PFC Caregiver & Household Screening brand, many more private estates, family offices, and personal service agencies. Imperative has been named a Best Places to Work, the Texas Association of Business' small business of the year, and is accredited by the Professional Background Screening Association.  Mike shares his insight from 25+ years of HR-entrepreneurship on the Good Morning, HR podcast, where each week he talks to business leaders about bringing people together to create value for customers, shareholders, and community. Mike has been recognized as an Entrepreneur of Excellence by FW, Inc. and has twice been recognized as the North Texas HR Professional of the Year.  Mike serves as a board member of a number of organizations, including the Texas State Council, where he serves Texas' 31 SHRM chapters as State Director-Elect; Workforce Solutions for Tarrant County; the Texas Association of Business; and the Fort Worth Chamber of Commerce, where he is chair of the Talent Committee. Mike is a certified Senior Professional in Human Resources (SPHR) through the HR Certification Institute and a SHRM Senior Certified Professional (SHRM-SCP). He is also a Yoga Alliance registered yoga teacher (RYT-200) and teaches multiple times each week. Mike and his very patient wife of 28 years are empty nesters in Fort Worth.  Learning Objectives: Understand why AI disruption is fundamentally different from previous technology shifts in the workplace. Recognize cognitive rigidity and emotional responses that block effective adaptation to change. Apply neuro-adaptive leadership techniques to help teams respond productively to rapid disruption. 

What does it take to make billion-dollar decisions inside one of the most powerful companies in the world? In this episode of The 30 Minute Hour, we go inside the mind of former Google finance leader Lamont Johnson. From shaping financial strategy at global giants like Google, Coca-Cola, and McKesson to leading with purpose beyond the numbers, Lamont shares powerful insights on leadership, decision-making, mentorship, and why impacting lives is the real key to impacting the bottom line. This conversation will challenge how you think about success, leadership, and legacy! #LeadershipMindset#BusinessLeadership#GoogleLeadership#ExecutiveMindset#The30MinuteHour

In this episode of #TheShot of #DigitalHealth Therapy, Jim Joyce and I sit down with Carl Bradford Byers

A familiar format, a subtle shift, and something worth sticking around for. This episode includes an introduction to the next chapter of Independent Insights. HostSuzanne Feeney, PharmDSr. Director, Pharmacy SolutionsMcKesson / Health MartGuestsBritney Woods, PharmDSr. Manager, Community PharmacyMcKesson / Health MartThe views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

"Why are we paying $10,000 for a $30 drug?"My guest this week is Pramod John, a former Silicon Valley tech entrepreneur who entered the healthcare space to tackle the largest economic problem in the country: skyrocketing healthcare costs. Pramod quickly realized that healthcare's dysfunction is actually not a technology problem - it is a deeply ingrained problem with economic incentives.In this episode, we dive into the murky waters of Pharmacy Benefit Managers (PBMs) and why the traditional model is designed to drive up costs rather than lower them. We discuss the shocking statistics of drug spend (where 2% of people account for 55% of the costs), why FDA approval doesn't always mean a drug is effective (using the infamous Alzheimer's drug as an example), and the implications of recent fiduciary lawsuits like the one against J&J.Pramod explains how we can bring common sense back to healthcare by treating drugs like any other consumer purchase. By utilizing an "open market" drug management model, he argues that we can effectively replace traditional PBMs with transparent transaction processing software - saving plans 30% to 50% without relying on restrictive formularies or rebate games. Tune in this week for a clear roadmap for how to actually fix the irrational economics of our healthcare system.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit ParetoHealth.com to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Why We Talk About Cost Instead of Quality (00:02:42) From Silicon Valley & Defense Tech to McKesson (00:10:43) Why Healthcare is NOT a Technology Problem (00:15:53) Fiduciary Responsibility & The J&J Lawsuit (00:19:03) The Butter Knife vs. Pareto: The Math of Drug Spend (00:23:54) Building an "Open Market" Alternative to PBMs (00:29:40) Why Doctors Fly Blind on Drug Pricing & Formularies (00:35:42) FDA Approval vs. Real-World Efficacy (00:45:44) How to Actually Fix the Model: The Real-Time "Pause" (00:58:36) Why International Sourcing & PAPs Aren't the Fix (01:11:00) Replacing PBMs with Simple Transaction SoftwareKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

"Why are we paying $10,000 for a $30 drug?"My guest this week is Pramod John, a former Silicon Valley tech entrepreneur who entered the healthcare space to tackle the largest economic problem in the country: skyrocketing healthcare costs. Pramod quickly realized that healthcare's dysfunction is actually not a technology problem - it is a deeply ingrained problem with economic incentives.In this episode, we dive into the murky waters of Pharmacy Benefit Managers (PBMs) and why the traditional model is designed to drive up costs rather than lower them. We discuss the shocking statistics of drug spend (where 2% of people account for 55% of the costs), why FDA approval doesn't always mean a drug is effective (using the infamous Alzheimer's drug as an example), and the implications of recent fiduciary lawsuits like the one against J&J.Pramod explains how we can bring common sense back to healthcare by treating drugs like any other consumer purchase. By utilizing an "open market" drug management model, he argues that we can effectively replace traditional PBMs with transparent transaction processing software - saving plans 30% to 50% without relying on restrictive formularies or rebate games. Tune in this week for a clear roadmap for how to actually fix the irrational economics of our healthcare system.Thank you to our 2026 sponsors!ParetoHealth: ParetoHealth empowers midsize employers with a long-term solution to reduce volatility and lower overall health benefits costs. Visit ParetoHealth.com to learn more.Samaritan Fund: A program that connects those who need help to the support they need. We are proud to offer the Samaritan Fund Program. Visit SamaritanFundProgram.com to learn more.Vālenz Health: We're Vālenz Health, your partner in improving health literacy, reducing plan spend, and delivering high-value healthcare. Visit ValenzHealth.com to learn more.Imagine360: Imagine360 helps self-funded employers save on healthcare with smarter health plans. Cut expenses by 20-30% with custom solutions. Contact us today at Imagine360.com.Chapters:(00:00:00) Intro: Why We Talk About Cost Instead of Quality (00:02:42) From Silicon Valley & Defense Tech to McKesson (00:10:43) Why Healthcare is NOT a Technology Problem (00:15:53) Fiduciary Responsibility & The J&J Lawsuit (00:19:03) The Butter Knife vs. Pareto: The Math of Drug Spend (00:23:54) Building an "Open Market" Alternative to PBMs (00:29:40) Why Doctors Fly Blind on Drug Pricing & Formularies (00:35:42) FDA Approval vs. Real-World Efficacy (00:45:44) How to Actually Fix the Model: The Real-Time "Pause" (00:58:36) Why International Sourcing & PAPs Aren't the Fix (01:11:00) Replacing PBMs with Simple Transaction SoftwareKey Links for Social:@SelfFunded on YouTube for video versions of the podcast and much more - https://www.youtube.com/@SelfFundedListen/watch on Spotify - https://open.spotify.com/show/1TjmrMrkIj0qSmlwAIevKA?si=068a389925474f02Listen on Apple Podcasts - https://podcasts.apple.com/us/podcast/self-funded-with-spencer/id1566182286Follow Spencer on LinkedIn - https://www.linkedin.com/in/spencer-smith-self-funded/Follow Spencer on Instagram - https://www.instagram.com/selffundedwithspencer/

AI is revolutionizing how health information is managed. Utilizing sophisticated algorithms, it can assist professionals in making more informed decisions. For instance, optical character recognition (OCR) can read and interpret medical records, identifying potential compliance issues and ensuring every page represents the correct patient.  In this episode, host Sandy Vance chats with Anupriyo Chakravarti, the Chief Technology and Product Officer at Verisma, about how healthcare organizations can use intelligent automation to reduce risk and uncover compliance gaps in order to free staff to work at the top of their license.  In this episode, they talk about: What Verisma can do for healthcare organizations Use case examples Some of the risks Verisma mitigates by finding missteps like unauthorized disclosures  AI is taking over the world of informatics Enabling people to work at the top of their license is critical People are not anti-AI, they are anti-opacity A Little About Anupriyo: Anupriyo Chakravarti joined Verisma Systems, Inc. in 2017 as the Senior Vice President of Research and Development. Anupriyo brings 25 years of experience as a highly effective leader in healthcare IT product management and software development for Fortune 500 companies and startups. Anupriyo joined Verisma after serving as vice president of product management and marketing at McKesson, where he led the product management and marketing functions of the Extended Care Services (ECS) business unit. Before McKesson, he worked for 11 years at Surgical Information Systems (SIS), where he led software development, and ultimately product management, to deliver solutions for the surgery and anesthesia departments at health systems and ambulatory surgery centers. Prior to working with SIS, Anupriyo worked for Arthur Andersen, Ryder Dedicated Logistics, IBM and TATA Motors. Anupriyo has a bachelor's degree in mechanical engineering from IIT Roorkee in India.   

DNA tests have become very popular, whether to find long lost relatives, to trace your ethnicity, or maybe to find out some answers about your health – but sometimes the results can bring up more questions than answers...That was certainly the case for Summer McKesson, who joins Andrea to discuss…

Community oncology is playing an increasingly important role in how cancer care is delivered across the United States, with a growing share of patients treated outside large academic medical centers. In this sponsored episode of The Top Line, host Chris Hayden sits down with Kirk Kaminsky, executive vice president and group president of North American Pharmaceutical Services for McKesson, to examine what this shift means for patients, providers and the industry. Kaminsky explains how advances in cancer science have transformed many diagnoses into long-term conditions, increasing the need for accessible, high-quality care in local communities. He discusses the challenges community practices face as innovation accelerates, including evolving reimbursement models, operational pressures and the adoption of new technologies. The conversation also explores the role of community oncology in expanding access to clinical trials and accelerating research, as well as how artificial intelligence is being used to improve both clinical and administrative workflows. Kaminsky shares his outlook on the next five to 10 years of cancer care and why supporting community oncology will be critical to continued progress. Listen to the full interview to learn more.See omnystudio.com/listener for privacy information.

Join us for a special live episode of Independent Insights as we sit down with members of the National Independent Advisory Board (NIAB), at McKesson ideaShare, to explore their vision for the future of pharmacy. Hear firsthand what they've learned from McKesson ideaShare (MiS), what excites them most about the road ahead, and how they're working to elevate the voice of independent pharmacy across the country.HostSuzanne Feeney, PharmDSr. Director, Pharmacy SolutionsMcKesson / Health MartGuestsShelby Knott, PharmDOwnerWarren PharmacyEmmanuel Ayanjoke, PharmDOwnerAltev Community PharmacyGhada Abukuwaik, RPhOwnerCuremed Pharmacy ResourcesTune into Episode 16: Episode 16: Creating Pharmacy's FutureTo listen to APhA President Randy McDonough and Chief Pharmacist Nancy Lyons as they discuss urgent changes and a bold vision for the future of independent pharmacy on this episode of Independent Insights. ReferencesListen to Episode 17: From Aisles to Action: Welcoming Legislators into Your Pharmacy.The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

The transition from being a rockstar in your vertical to leading at the C-suite level is one of the hardest jumps in modern business.  Not because you aren't capable, but because the job changes faster than anyone prepares you for, and the timeline to become effective has collapsed from years to months. You used to have a multi-year runway to listen, learn, and settle in. Now the proving ground has accelerated, and you're expected to think enterprise-wide, set direction, shape culture, and operate with conviction almost immediately. And that's where so many leaders get blindsided. They step into the role with deep expertise, strong track records, and every intention of succeeding. But they quickly discover that the behaviors that powered their rise don't automatically translate to the top job.  The stakes are higher, the scrutiny is sharper, and the margin for a slow learning curve is gone. Boards, investors, and teams are already forming judgments before you've even taken your seat. And without realizing it, new executives find themselves operating on outdated instincts in a completely different environment. Bill Koch is a former CEO who now coaches leaders navigating some of the most high-pressure environments. He helps new CEOs compress the transition, build real executive presence, and operate with clarity and confidence. In this episode, we talk about how to accelerate that transition, how to understand how you're actually being perceived, and how to adapt fast enough to avoid losing ground in your first critical months.   You'll also learn: Why the jump from functional mastery to C-suite leadership is so challenging How the timeline for becoming effective has collapsed, and what that means for new executives. The behaviors that helped you rise and why they can quietly derail you in a senior role. How to understand the difference between vertical thinking and enterprise thinking. Why a 360 assessment is often the first real mirror a new executive has ever seen. How boards and teams perceive you long before you think they do Why private equity environments expose leadership weaknesses faster than any other setting. How to cultivate executive presence that signals quiet confidence, not overcompensation. The importance of building a “personal boardroom” to think clearly under pressure.   About the Guest Bill Koch is an executive coach with more than 25 years of C-suite and senior leadership experience across public companies, private enterprises, and private equity–backed firms. A former CEO himself, Bill brings a rare blend of operational depth, boardroom insight, and executive maturity to his coaching practice. His work centers on one mission: helping high performers become highly effective enterprise leaders. For more than a decade, Bill has served as a trusted advisor to CEOs and senior executives navigating high-pressure, high-visibility roles. He coaches leaders across Fortune 500 companies, growth-stage organizations, and academic institutions—guiding them through pivotal transitions, accelerated timelines, and complex leadership challenges. His clients turn to him to gain clarity, sharpen judgment, and build the confident executive presence required to lead at the top. Bill's clients include American Express, Apple, Boeing, Goldman Sachs, John Deere, Mars, MGM, McKesson, Toyota, and others. To learn more, visit https://www.kochleadership.com/ or read Bill's latest insights on Forbes.    About Your Host Craig Picken is an Executive Recruiter, writer, speaker, and ICF Trained Executive Coach. He is focused on recruiting senior-level leadership, sales, and operations executives in the aviation and aerospace industry. His clients include premier OEMs, aircraft operators, leasing/financial organizations, and Maintenance/Repair/Overhaul (MRO) providers, and since 2008, he has personally concluded more than 400 executive-level searches in a variety of disciplines. Craig is the ONLY industry executive recruiter who has professionally flown airplanes, sold airplanes, and successfully run a P&L in the aviation industry. His professional career started with a passion for airplanes. After eight years' experience as a decorated Naval Flight Officer – with more than 100 combat missions, 2,000 hours of flight time, and 325 aircraft carrier landings – Craig sought challenges in business aviation, where he spent more than 7 years in sales with both Gulfstream Aircraft and Bombardier Business Aircraft. Craig is also a sought-after industry speaker who has presented at Corporate Jet Investor, International Aviation Women's Association, and SOCAL Aviation Association.    Subscribe, Rate & Review Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm, so our show reaches more people. Thank you! 

One on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USIn this powerful episode of the True Life Podcast, host George Monty delivers a hard-hitting “daily transmission” exposing how corporations and systems deliberately manufacture scarcity to drive profits, control populations, and prevent true abundance from reaching everyday people. Drawing on real-world examples from food, housing, medicine, and more, George reveals the patterns of consolidation, surplus destruction, and artificial shortages that keep society desperate and divided. He calls for recognition, documentation, and rebellion against this “scarcity weapon,” urging listeners to investigate local resources and demand the withheld plenty. This episode is a wake-up call to see beyond the narratives of inflation and supply chain issues to the engineered theft of abundance.Host: George MontyPodcast: True Life PodcastDuration: Approximately 10-15 minutes (based on transcript length)Release Date: Estimated based on content references (late 2025)Listen Here: Explore more episodes and connect with George Monty on the TrueLife platform. Key Timestamps & HighlightsGeorge's monologue flows as a continuous narrative, but we've broken it down into thematic sections with approximate timestamps for easy navigation:•  00:00 - 01:00: The Illusion of Struggle George opens by challenging the narrative that you're failing—it's engineered starvation in abundance. He prompts listeners to check their finances and see how earnings vanish despite higher pay, labeling it “2025's manufactured scarcity” designed for control and extraction.•  01:00 - 02:30: From Ancient Famines to Modern Engineering Contrasting natural famines with today's deliberate hunger, George highlights U.S. food production capacity (enough for 10 billion people) versus 34 million facing food insecurity amid record corporate profits.   He exposes the “machine that weaponizes emptiness.” •  02:30 - 04:00: Food Shortages Exposed•  2024 egg shortage: Not avian flu, but corporate consolidation by Cal-Maine Foods (20% market control), leading to tripled prices and $535 million in profits. •  2022-2024 baby formula crisis: Abbott's monopoly (43% market) caused shutdowns, boosting stock 34% while parents turned to black markets. https://www.theguardian.com/us-news/2025/apr/09/doj-egg-prices-rise-cal-maine-profits•  04:00 - 05:00: Housing and Tech Hoarding•  Housing crisis: 16 million vacant homes in the U.S. versus over 600,000 homeless, as empty properties prove more profitable. •  2025 semiconductor shortage: TSMC's alleged deliberate restrictions via leaked emails to maintain pricing, with chips stockpiled while car prices soar.  (Note: Related to trade secret leaks; broader shortage context available.)https://unitedwaynca.org/blog/vacant-homes-vs-homelessness-by-city/•  05:00 - 06:30: Surplus Destruction and Corporate Mandates George uncovers patterns of destroying goods under USDA/EPA/FDA protocols lobbied by corporations.  He cites the 2024 NASS report (Appendix G, p. 847) on 2.3 billion pounds of produce destroyed to avoid “market destabilization.”  Kroger's 2019 leaked memo advocates “optimal scarcity ratios” for urgency buying. https://www.usda.gov/about-usda/news/press-releases/2023/09/20/usda-expands-efforts-prevent-and-reduce-food-loss-and-wastehttps://www.nass.usda.gov/Charts_and_Maps/Crop_Progress_&_Condition/2024/index.phphttps://www.nationofchange.org/2024/09/03/corporate-greed-exposed-kroger-admits-to-price-gouging-on-milk-and-eggs-amid-antitrust-trial/•  06:30 - 08:00: The Scarcity Playbook Step-by-step breakdown: Consolidate supply, engineer shortages (restrict, destroy surplus), profit from desperation. Blame shifts to weather or labor, not architects.•  08:00 - 10:00: Historical and Ongoing Examples•  2008 housing crisis: Banks held 3.5 million foreclosures as “shadow inventory” to keep prices high. https://en.wikipedia.org/wiki/Subprime_mortgage_crisis•  2020 toilet paper: Procter & Gamble and Georgia-Pacific (55% control) restricted distribution for 300% price surges at 64% capacity. https://www.resourcewise.com/market-watch-blog/are-we-really-running-out-of-toilet-paper-in-the-covid-crisis•  2021 lumber: Weyerhaeuser and West Fraser (40% control) quadrupled prices with underused mills. https://markets.businessinsider.com/news/stocks/lumber-prices-hit-record-highs-soaring-past-year-2021-4-1030299977•  2023 prescription drugs: Wholesalers like McKesson, Cardinal, and AmerisourceBergen (95% control) restrict insulin ($2 production cost) amid shortages. https://www.mmm-online.com/home/channel/drug-shortages-in-america/•  2025 water: Nestlé, Coca-Cola, Pepsi (75% bottled water) amid contaminated public supplies. https://www.grandviewresearch.com/industry-analysis/bottled-water-market•  10:00 - 11:30: Broader Patterns of Waste Amazon destroys 2 million unsold products yearly for scarcity pricing.  Pharma discards effective expired meds.  Energy firms flare gas for 10 million homes.  McKinsey's 2023 report recommends 15-20% below-demand inventory for margins.  Supply chain “disruptions” post-2020? Traffic normalized by Q3 2021, but prices stayed high via throttling. https://www.ethicalconsumer.org/ethical-campaigns-boycotts/amazons-burning-approach-unsold-returned-productshttps://pmc.ncbi.nlm.nih.gov/articles/PMC10834166/

In this episode, host Suzanne Feeney, PharmD, Senior Director, Pharmacy Solutions at McKesson Health Mart and guest Jaime Montuoro, PharmD, Director of Education & Practice Advancement at McKesson Health Mart, unpack two strategies you can deploy now: PGY1 community-based residencies and pharmacy credentialing. You'll learn how residency trained pharmacists can elevate clinical care in workflow, fuel change and help launch billable services. Then, we get practical on credentialing—why becoming “provider ready” matters and how claiming your team's Pharmacy Profiles credentials streamlines payer opportunities. Jaime shares real-world wins, including how Bryant Family Pharmacy partnered with a resident to implement prescriptive authority programs patients were willing to pay for. If you're ready to move beyond the transaction and build sustainable, community anchored care, this playbook will help you start today. HostSuzanne Feeney, PharmDSr. Director, Pharmacy Solutions McKesson / Health MartGuestJaime Montuoro, PharmDDirector, Education and Practice AdvancementMcKesson / Health MartResourcesTune into Episode 11: Maximizing Operations Through Proactive Workflow Health Mart Pharmacies can access Health Mart University (HMU) for:Health Mart pharmacists to claim their CE credit for weekly GameChangers episodesReferencesLearn more about the Health Mart Postgraduate Year One Community-based Pharmacy Residency Program herePharmacy Profiles is a pharmacy-friendly database that allows pharmacy teams to showcase their training and certifications in one place. If you're a Health Mart pharmacy demonstrate your pharmacy's readiness to receive potential patient care opportunities more quickly by having your pharmacy professionals claim their MYPROFILE. Learn more here: my.pharmacyprofiles.com. Pharmacy Profiles is a Strategic Health Alliance II, Inc., vendor.  The views and opinions expressed in this podcast are those of the guest and do not necessarily represent the views or positions of Health Mart, McKesson or its affiliates or subsidiaries ("McKesson”). The information provided herein is for informational purposes only and does not constitute the rendering of clinical, legal or other professional advice by McKesson.

In this 200th EPISODE of the Great Trials Podcast, Steve Lowry hosts a detailed discussion with Randy Jordan, an experienced trial lawyer from HunterMaclean in coastal Georgia. The focus is on the complex case of Poppell v. Cardinal Health, McKesson Corporation, and Smith Corporation, which involved 21 plaintiffs and highlighted the opioid crisis.   CASE SUMMARY:  In the case of Poppell, et al, vs McKesson, et al, twenty-one plaintiffs sued three wholesale medicine and medical supply distributors, including McKesson Corporation, Cardinal Health, and J.M. Smith. Under Georgia's Drug Dealer Liability Act, the plaintiffs claimed that the three companies acted as illegal drug dealers in filling orders for opioid medications placed by pharmacies and hospitals in Coastal Georgia. The plaintiffs, mostly children of the addicts, claimed extensive mental and psychological damage resulting from their parents' addictions. (READ MORE)   RANDY JORDAN: He is a uniquely experienced trial attorney, having tried well over one hundred jury cases in state and federal courts across the country. For over thirty years, Randy has defended some of America's largest railroads in a wide array of business and tort matters, including the defense of hundreds of asbestos and other toxic exposure claims. In recent years, Randy has served as lead trial counsel for a major medical supply and distribution company in its opioid litigation. Randy frequently appears in state and federal appellate courts throughout the Southeast and is a frequent speaker on issues relating to the transportation industry. (READ FULL BIO)   CONNECT WITH OUR GUEST: HunterMaclean on X HunterMaclean on LinkedIn HunterMaclean on YouTube HunterMaclean Online   LISTEN TO PREVIOUS EPISODES & MEET THE TEAM: Great Trials Podcast Show Sponsors: Legal Technology Services  Harris Lowry Manton LLP - hlmlawfirm.com Production Team: Dee Daniels Media Podcast Production   Free Resources: Stages Of A Jury Trial - Part 1 Stages Of A Jury Trial - Part 2

Up first, Inspirogene-by-McKesson with Joe DePinto   InspiroGene" is a dedicated business unit launched by McKesson in October 2024, focused solely on supporting the commercialization of cell and gene therapies (CGTs). It leverages McKesson's expertise in supply chain, logistics, and specialty pharmacy to help manufacturers, payers, and providers navigate the complex CGT landscape. https://www.mckesson.com/business-solutions/our-businesses/inspirogene-by-mckesson/ Our featured interview: Sponsored by MatchRX The TrumpRx Playbook for Independent Pharmacies CEO of MatchRx Johny Kello co-hosts with Todd Eury featuring our guest speaker, Dae Lee, Pharm.D., Esq., CPBS. Dae is a pharmacist-attorney and a Shareholder in the FDA & Biotechnology practice at Buchanan Ingersoll & Rooney. What makes Dae especially valuable for this conversation is that he's not just reading policy from 30,000 feet — he represents pharmacies every day in high-stakes fights with PBMs, from audits and reimbursement disputes to network suspensions and terminations. So, when we talk about TrumpRx — how it works, what it could break, and what independents should do next — Dae can translate the legal and contracting reality into real-world consequences behind the counter. Connect with MatchRX: MatchRX.com Special Message from Greg Reybold with APCI, update of the "Pharmacists Fight Back Act" Connect with Greg: https://www.apcinet.com/ Next, we talk with Dr. Jessica Daley PharmD Fractional Supply Chain and Operations Executive, with Pharma Logistics, we dicuss drug shortages and strategies for 2026. Connect with Jessica: https://www.linkedin.com/in/jessicaldaley/ Last interview, a suprise message from International Pharmacy 50 Pharmacist & Author Katrina Azer, announcing her new book  https://www.katrinaazer.com/#books   The TrumpRx Playbook for Independent Pharmacies - with MatchRX | TWIRx 

About Lori Logan:Lori Logan is the president and CEO of NASCO, where she leads with a vision to merge innovation with a strong foundation in healthcare. Based in Englewood, Colorado, she brings over two decades of leadership across healthcare's payer, provider, and technology sectors. Known for her curiosity, analytical mindset, and collaborative leadership, Lori has consistently driven growth, transformation, and measurable impact. Her career includes leading multimillion-dollar projects, overseeing teams of hundreds, and managing large-scale integrations and mergers, and acquisitions (M&A) initiatives. Previously, she held senior roles at athenahealth, Geneia, Paladina Health, TriZetto, UnitedHealthcare, Cigna, and McKesson—where she launched groundbreaking products and strategies that improved care coordination and operational efficiency. Recognized for her strategic acumen and results-driven approach, Lori has earned industry accolades, including the TriZetto CEO Pinnacle Award and the Thomson Reuters Healthcare Advantage Award. Her mission remains clear: to reimagine healthcare and create healthier outcomes and lives.Things You'll Learn:Legacy infrastructure hinders scalability; health plans require a modern administrative “chassis” to package benefits, administer payments, and operationalize innovation. This goes well beyond traditional claims systems.Analytics must merge claims, clinical, and engagement data with medical economics precision. Insights then have to reach providers and advocates so care is both effective and reimbursable.A significant amount of value now resides outside of claims in disease management, digital tools, and condition management programs. Members need clear navigation and transparency on what they have, where to go, and what it costs.Provider enablement is essential for value-based care. Success depends on aligned incentives, shared operations, coaching, and trust between plans and providers.Strategic investments should prioritize scalable administration, robust operations, and data pipelines. These foundations let plans attribute value, manage risk, and drive affordability at scale.Resources:Connect with and follow Lori Logan on LinkedIn.Follow NASCO on LinkedIn and explore their website.

It's the Live, Laugh, Larceny Halloween special, and we're celebrating spooky season by getting down and dirty — deep in the bowels of October. This week, Trevin faces a full-blown Halloween dilemma after realizing spiders are the only creature he likes less when they have a big butt. Because, really — anything that plump and poisonous can't be trusted. Meanwhile, Amanda's questioning her life choices after watching the Is It Cake? Halloween special and realizing that hobbyists are somehow better at everything than she is. Our game this week is a frightful All Hallow's Eve edition of This or That, where Amanda forces Trevin to choose between the true terrors of October: slasher films or psychological horror? Cute or scary costumes? Carve or paint your pumpkins? Foggy nights or full moons? Scream franchise or Halloween classics? We're tackling every haunted dilemma that defines the season. For storytime, Amanda shares the eerie tale of Shannon Dennis and Tina Jamarillo of Barstow, California — two women who let the Halloween spirit possess them a little too much. After police receive reports of a dead body in the desert, these grown adults might just end up looking like real dummies. Trevin's story opens with a nomination for the scariest Halloween costume ever: a suit. In a chillingly relatable tale of corporate America, capitalism, and existential dread, meet Bo Whitener, a Georgia man working for McKesson's pharmaceutical distribution center. When a massive CEO pension check lands in the wrong hands, Bo decides to dress up as the big boss himself for the company Halloween party — a move that might earn him a police call, a suspension, or a long interrogation by a middle manager. Beyond the usual Halloween tropes, today's episode ties together Spirit Halloween, candy corn, and — most importantly — bowels. Put on your waterproof boots and light your jack-o'-lanterns, because this true petty crime and comedy podcast special dives deep — uncomfortably deep — into the bowels of spooky season. Join our Facebook Group: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/livelaughlarcenydoomedcrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For ad-free episodes and lots of other bonus content, join our Patreon! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/LiveLaughLarceny⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Check out our website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow us on TikTok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you have a crime you'd like to hear on our show OR have a personal petty story, email us at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠livelaughlarceny@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or send us a DM on any of our socials! Learn more about your ad choices. Visit podcastchoices.com/adchoices

HLI Partners co-founders Joe Hills and Josh Lipoff share how they built a boutique CRE firm, Orlando industrial/office trends, and strategies to win deals.The Crexi Podcast connects CRE professionals with industry insights built for smart decision-making. In each episode, we explore the latest trends, innovations and opportunities shaping commercial real estate, because we believe knowledge should move at the speed of ambition and every conversation should empower professionals to act with greater clarity and confidence.  In this episode of The Crexi Podcast, Shanti Ryle sits with Joe Hills and Josh Lipoff to discuss their transitions from major firms to launching their own company, competitive strategies, and the intricacies of the Central Florida market. Hills and Lipoff share insights into their career paths, the importance of mentorship, and the creative solutions they employ to meet tenant needs. They also highlight market trends, investment strategies, and the challenges and opportunities in Orlando's evolving CRE landscape.Meet Joe Hills and Josh Lipoff: Founders of HLI PartnersCareer Beginnings in Commercial Real EstateEarly Challenges and MentorshipForming a Strong PartnershipLaunching HLI PartnersStrategies for Success in CRENavigating Market ChallengesCurrent Trends in Central Florida's Industrial MarketSpecialty Tenants and Market DynamicsImpact of COVID-19 on Home BuildingShifts in Industrial Space DemandBuild-to-Suit and Infill PricingMacro Factors Influencing Orlando's MarketOpportunities and Risks in Orlando's MarketRapid Fire Questions and AdviceFinal Insights and Parting Words About Joe Hills:Over the course of his career, Joe Hills has been involved in over 475 deals, closing more than 1 billion dollars in transaction volume. In 2020, Joe played a key role in the new location of a 119,684 s.f. building for Paradise Grilling System. Thereafter in 2021, Joe assisted in the building of an additional 200,000 s.f. warehouse space for Signature Brands as well as the renewal of Samsung's current lease for their 550,000 s.f. space. With an extensive track record in the industrial sector, Joe has developed a strategic orientation towards areas of manufacturing. In the span of his 15-year career in commercial real estate, Joe has successfully leased and sold more than twenty-five million square feet of space with transactions totaling more than $1 billion. About Josh Lipoff:Josh Lipoff brings over 20 years of corporate business development and has successfully negotiated several million square feet of Central Florida's Industrial team transactions. Prior to joining HLI Partners, Josh spent 12 years with JLL's Industrial team in Orlando. During his career, Josh specialized in Tenant Representation, build-to-suit and site selection, financial analysis, and lease and contract evaluation. National clients served over the years have included: Brookfield Properties, Stonemont, McKesson, Ocean Spray, Walgreens, Mattress Firm, Sysco, Freeman, Iron Mountain, United Stationers, and Kellogg's. For show notes, past guests, and more CRE content, please check out Crexi's blog.Looking to stay ahead in commercial real estate? Visit Crexi to explore properties, analyze markets, and connect with opportunities nationwide. Follow Crexi:https://www.crexi.com/​ https://www.crexi.com/instagram​ https://www.crexi.com/facebook​ https://www.crexi.com/twitter​ https://www.crexi.com/linkedin​ https://www.youtube.com/crexi

Investor Nancy Brown joins us at Aspen Ideas Health to share her blueprint for impactful investments. Identify public health breakthroughs that deliver measurable cost and quality improvements — then show how they can thrive in the marketplace. You don't have to look far to see this playbook in action. One of the year's biggest health exits, Omada Health, is a digital version of the CDC's Diabetes Prevention Program. At Oak HC/FT, Nancy has partnered with entrepreneurs who are redefining how America stays healthy — and she's eager to see more people with public health roots take the leap into building impactful companies.Please note: this conversation happened before HR1 was passed, so big Medicaid cuts were a threat but not yet a reality when we spoke.In this episode, we discuss:Lessons from Todd Park in the early days of athenahealthHow to turn good ideas into great businessesNancy's advice in an era of policy disruption: keep on building and proving valueThe lesson Kaiser Permanente is still teaching usNancy reminds us that in reality, even a brilliant idea needs to have ROI built in:“We look for entrepreneurs, for innovators, who have really defined a way in which to find a cohort of patients, it could be pregnant Medicaid moms... And they have identified if they apply a certain clinical process consistently to that population, they will get a consistently good outcome, quality outcome, and they can do it in a sustainable [way] at a sustainable price.”Relevant LinksRead Oak HC/FT's AI Investment PolicyExplore businesses Nancy mentioned from Oak HC/FT's investment portfolio:Maven ClinicOshi Health About Our GuestNancy Brown is a General Partner at Oak HC/FT, a leading venture and growth equity firm investing in transformative healthcare and fintech companies. Since joining Oak HC/FT at its inception in 2014, Ms. Brown has focused on identifying and supporting technology-enabled healthcare services that deliver measurable clinical and financial impact. She focuses on growth equity and early-stage venture investments in healthcare, serving on the boards of innovative companies such as Firefly Health, Groups Recover Together, InterWell Health, Maven Clinic, Oshi Health, Regard, Unite Us, and Wayspring. Her portfolio also includes Noom, TurningPoint Healthcare Solutions, Limeade (ASX: LME), OncoHealth, and OODA Health.Ms. Brown brings over three decades of operational and leadership experience to her investment role. Prior to Oak HC/FT, she was Vice President of Strategy and Business Development at McKesson Technology Solutions and Chief Growth Officer at MedVentive (acquired by McKesson in 2012). Previously, she served as Senior Vice President of Clinical Services and Corporate Development at athenahealth, and earlier held senior roles at McKesson and Harvard Community Health Plan. She also co-founded Abaton.com, one of the first web-based clinical solution companies, which was later acquired by McKesson.A graduate of the University of New Hampshire (B.S. in Zoology) and Northeastern University (MBA), Ms. Brown is an active mentor and advisor. She serves on Northeastern's D'Amore‑McKim School of Business Dean's Executive Council and is involved in the Roux Institute's Future of Healthcare Founder Residency program.

On "This Week in Pharmacy" for September 26th, we're talking about Trust in Healthcare, World Pharmacists Day, and Cell & Gene Therapy. Today's co-host is Dr. Melissa Smith, PharmD CPH with Florida PGx Consulting LLC. https://www.floridapgxconsulting.com/  First, #TWIRx News - the FDA approves Inluriyo imlunestrant on 9/25/2025 which is to treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. (https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)  Second, Nested-Knowledge - is going to revolutionize information access and leverage. This is a powerful tool with evidence synthesis tools for medical researchers. This will help accelerate, collaborate, automate and share the latest and personalized treatment plans. (https://nested-knowledge.com/) Next, announcing "Evidence based Podcasting", the new standard in audio learning for Providers and next level in podcast Continuing Medical Education (CME). (https://pharmacypodcast.com/2025/09/26/evidence-based-podcasting-and-the-future-of-medical-education/ ) Shout out to Nick Calla with Orsini, a leader in rare disease pharmacy solutions, has been chosen by Crinetics Pharmaceuticals, Inc., as a specialty pharmacy partner for PALSONIFY™ (paltusotine), a nonpeptide, selectively-targeted somatostatin receptor type 2 nonpeptide (SST2) agonist. (https://www.wvnews.com/news/around_the_web/partners/pr_newswire/subject/licensing_marketing_agreements/orsini-selected-as-specialty-pharmacy-partner-for-crinetics-palsonify-paltusotine/article_9b42bfe7-69a6-58be-98ff-5e2245145415.html) Today we have two guest Pharmacists to dig into the "Trust in Healthcare" theme of today's #TWIRx -- the godfather of Functional Pharmacy Robert Kress RPh., and Dr. Lauren Castle, PharmD, MS, AFMC - Founder & CEO of Functional Medicine Pharmacists Alliance. Who do you trust? What information is trustworthy and why?  Our special feature is updates on 'Cell & Gene Therapy' with McKesson's Head of Cell Gene Advanced Therapies, Joe DePinto at InspiroGene!  (https://inspirogene.com/)  Today's TWIRx is sponsored by 'Sykes & Company' the Pharmacy Accounting Jedi Masters and Independent Pharmacy Cooperative (IPC) and how they're revolutionzing digital health and new revenues with the iCare+ System!    Trust Matters, Cell and Gene, & World Pharmacists Day | TWIRx

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover the shocking assassination of Charlie Kirk, Russian drones breaching NATO airspace, Trump's war on Venezuela's cartels, Mexico's tariff fight with China, a pharmaceutical victory in Tennessee, and new revelations in the 9/11 families' lawsuit against Saudi Arabia. From political violence at home to dangerous escalations abroad, today's brief carries heavy news on a day of prayer and remembrance.   Charlie Kirk Assassinated in Utah: The 31-year-old Turning Point USA founder was gunned down while speaking at Utah Valley University. President Trump called him “a martyr for truth and freedom” and ordered flags at half-staff. Video shows a sniper shot to the neck from a rooftop as Kirk addressed thousands of students. MSNBC sparked outrage with coverage that suggested Kirk's “awful words” made his death inevitable. Bryan warns, “The seal has now been broken: if you make those arguments or say those words, you're fair game too.”   Russian Drones Violate Polish Airspace: NATO confirms 19 Russian drones flew over 150 miles into Poland, with several shot down by Dutch and Polish jets. Bryan cautions that even an accident could spark a “Gulf of Tonkin–like incident” dragging NATO into direct war with Moscow.   Trump Escalates War on Venezuela's Cartels: After U.S. forces sank a drug boat killing 11, critics accuse Trump of overstepping presidential authority. War Secretary Pete Hegseth countered: “This strike sent a clear message: If you traffic drugs toward our shores, the United States military will stop you cold.”   Mexico Tariffs Chinese Imports: President Claudia Sheinbaum hikes tariffs on Chinese cars and textiles to 50 percent, aiming to shield Mexican workers and appease Trump's demands to close tariff loopholes. Bryan notes this could undercut Beijing's backdoor into U.S. markets.   Saving U.S. Antibiotics in Tennessee: Trump brokers a deal forcing Walmart and McKesson to buy amoxicillin from Bristol, Tennessee, rescuing America's last antibiotic factory from collapse. “Don't bet against America,” Bryan says, “because with leadership that actually loves this country, we will win.”   9/11 Families' Lawsuit Against Saudi Arabia Advances: A New York judge allows families to pursue claims that Saudi intel officers Omar al-Bayoumi and Fahad al-Thumairy aided hijackers. ProPublica reports al-Bayoumi was a Saudi intel asset in the U.S. coordinating with the GIP. Bryan calls for Trump to declassify CIA files: “It's time for some sunlight on what did or didn't happen that horrific day.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Take your personal data back with Incogni! Get 60% off an annual plan at incogni.com/TWR and use code TWR at checkout.     Keywords: Charlie Kirk assassination Utah, Trump martyr for truth, MSNBC Charlie Kirk coverage, Russian drones Poland NATO, Trump Venezuela drug cartels strike, Pete Hegseth drug cartels al Qaeda, Mexico tariffs Chinese imports Sheinbaum, Trump tariff war China backdoor, U.S. antibiotics Bristol Tennessee amoxicillin, Walmart McKesson Trump drug deal, 9/11 families lawsuit Saudi Arabia, Omar al-Bayoumi Saudi intel, Fahad al-Thumairy Saudi cleric, CIA Saudi 9/11 declassification